C22 Ceramide (d18:1/22:0)

TargetMol
Product Code: TAR-T37563
Supplier: TargetMol
CodeSizePrice
TAR-T37563-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37563-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37563-10mg10mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37563-25mg25mg£292.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37563-50mg50mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37563-100mg100mg£543.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
C-22 ceramide is an endogenous bioactive sphingolipid. Ceramides are involved in permeabilization of the mitochondrial outer membrane during apoptosis via the intrinsic pathway.[1] C-22 ceramide forms small channels in liposomes, whereas C-16 ceramide forms channels that can grow in size, suggesting that acyl chain length of ceramides is important in mitochondrial-mediated apoptosis. In addition, the mitochondrial-to-cytosolic stress response (MCSR) in C. elegans fed C-22 ceramide decreases following inhibition of Hsp6 (mortalin/Grp75/mtHsp70) using RNAi.[2]
CAS:
27888-44-4
Formula:
C40H79NO3
Molecular Weight:
622.1
Purity:
0.98
SMILES:
OC[C@H](NC(CCCCCCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC

References

Stiban J, et al. Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta. 2015 Feb;1848(2):561-7. Separovic D, et al. Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation. Int J Oncol. 2013 Dec;43(6):2064-72.